Spots Global Cancer Trial Database for Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung

Official Title: A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung

Study ID: NCT01236716

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Albumin paclitaxel plus carboplatin

Gemcitabine plus carboplatin

Study Description

Brief Summary: This trial is to study the efficacy of nab-PC vs. GC and evaluate toxicity of nab-PC in advanced squamous cell cancer of lung. The correlation between the efficacy of nab-PC and some biomarkers is also to be evaluated.

Detailed Description: Albumin-bound paclitaxel(nab-P) utilizes the albumin binding proteins,such as (gp60)/caveolin-1 (CAV1) and SPARC(secreted protein acidic and rich in cysteine), achieving high intratumoral paclitaxel accumulation. It is reported that CAV1 is overexpressed in squamous cell cancer(SQC), so it is possible that nab-PC is more highly active than GC in SQC of lung.